Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Burc Barin"'
Autor:
Burc Barin, Zisis Kozlakidis, Fabrizio Ricci, Longxiang Su, Constantinos Tsioutis, Susan C. Welburn, Catherine Ropert, Marco Iosa, Thomas Rawson, Jiufeng Sun, Eugenie R. Lumbers
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
Externí odkaz:
https://doaj.org/article/b254ecfb077f45a6b19efd1940d78c32
Publikováno v:
The Lancet Microbe, Vol 3, Iss 4, Pp e274-e283 (2022)
Summary: Background: Vaccination is an efficient strategy to control the COVID-19 pandemic. In north Cyprus, vaccine distribution started with CoronaVac followed by BNT162b2, and ChAdOx1 vaccines. An option to obtain a third booster dose with BNT162b
Externí odkaz:
https://doaj.org/article/e2a1f964abea4f65a2fcddbfb52eb7ed
Autor:
Burc Barin, Banu Elcin Yoldascan, Fatma Savaskan, Goncagul Ozbalikci, Tugce Karaderi, Hüseyin Çakal
Publikováno v:
Frontiers in Public Health, Vol 8 (2021)
Following the outbreak of COVID-19, multidisciplinary research focusing on the long-term effects of the COVID-19 infection and the complete recovery is still scarce. With regards to long-term consequences, biomarkers of physiological effects as well
Externí odkaz:
https://doaj.org/article/ed22c3ea352746d28e71dfa00f0de403
Autor:
Tugce Karaderi, Halin Bareke, Imge Kunter, Adil Seytanoglu, Ilgin Cagnan, Deniz Balci, Burc Barin, Mevhibe B. Hocaoglu, Nilufer Rahmioglu, Esra Asilmaz, Bahar Taneri
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
COVID-19 presentation is very heterogeneous across cases, and host factors are at the forefront for the variables affecting the disease manifestation. The immune system has emerged as a key determinant in shaping the outcome of SARS-CoV-2 infection.
Externí odkaz:
https://doaj.org/article/d316281e23a04f449d44548eb78b5c50
Autor:
Gaudensia Mutua, Bashir Farah, Robert Langat, Jackton Indangasi, Simon Ogola, Brian Onsembe, Jakub T Kopycinski, Peter Hayes, Nicola J Borthwick, Ambreen Ashraf, Len Dally, Burc Barin, Annika Tillander, Jill Gilmour, Jan De Bont, Alison Crook, Drew Hannaman, Josephine H Cox, Omu Anzala, Patricia E Fast, Marie Reilly, Kundai Chinyenze, Walter Jaoko, Tomáš Hanke
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 3, Iss C (2016)
We are developing a pan-clade HIV-1 T-cell vaccine HIVconsv, which could complement Env vaccines for prophylaxis and be a key to HIV cure. Our strategy focuses vaccine-elicited effector T-cells on functionally and structurally conserved regions (not
Externí odkaz:
https://doaj.org/article/4f123ec4f6fe44898924201105e4aa3e
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0135882 (2015)
Liver disease is a leading cause of mortality among HIV-infected persons in the highly active anti-retroviral therapy (HAART) era. Hepatitis C Virus (HCV) co-infection is prevalent in, and worsened by HIV; consequently many co-infected persons requir
Externí odkaz:
https://doaj.org/article/a7402b87484e4ca6b72f44205bf57f78
Autor:
Gloria Omosa-Manyonyi, Juliet Mpendo, Eugene Ruzagira, William Kilembe, Elwyn Chomba, François Roman, Patricia Bourguignon, Marguerite Koutsoukos, Alix Collard, Gerald Voss, Dagna Laufer, Gwynn Stevens, Peter Hayes, Lorna Clark, Emmanuel Cormier, Len Dally, Burc Barin, Jim Ackland, Kristen Syvertsen, Devika Zachariah, Kamaal Anas, Eddy Sayeed, Angela Lombardo, Jill Gilmour, Josephine Cox, Patricia Fast, Frances Priddy
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0125954 (2015)
Sequential prime-boost or co-administration of HIV vaccine candidates based on an adjuvanted clade B p24, RT, Nef, p17 fusion protein (F4/AS01) plus a non-replicating adenovirus 35 expressing clade A Gag, RT, Int and Nef (Ad35-GRIN) may lead to a uni
Externí odkaz:
https://doaj.org/article/44cb8cee2d1e45b9b74562d08c0bf833
Autor:
Gloria Omosa-Manyonyi, Harriet Park, Gaudensia Mutua, Bashir Farah, Philip J Bergin, Dagna Laufer, Jennifer Lehrman, Kundai Chinyenze, Burc Barin, Pat Fast, Jill Gilmour, Omu Anzala
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e110228 (2014)
Mucosal specimens are essential to evaluate compartmentalized immune responses to HIV vaccine candidates and other mucosally targeted investigational products. We studied the acceptability and feasibility of repeated mucosal sampling in East African
Externí odkaz:
https://doaj.org/article/70a16c6d75d64e228360c9a8dd13e1d4
Autor:
Freddie M Kibengo, Eugene Ruzagira, David Katende, Agnes N Bwanika, Ubaldo Bahemuka, Jessica E Haberer, David R Bangsberg, Burc Barin, James F Rooney, David Mark, Paramesh Chetty, Patricia Fast, Anatoli Kamali, Frances H Priddy
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e74314 (2013)
Efficacy of oral pre-exposure prophylaxis (PrEP) in prevention of HIV acquisition has been evaluated using a daily regimen. However, adherence to long term daily medication is rarely perfect. Intermittent regimen may be a feasible alternative. Precli
Externí odkaz:
https://doaj.org/article/d9d9a72efa234f8aa18422a582c5cb2a
Autor:
Gaudensia Mutua, Eduard Sanders, Peter Mugo, Omu Anzala, Jessica E Haberer, David Bangsberg, Burc Barin, James F Rooney, David Mark, Paramesh Chetty, Patricia Fast, Frances H Priddy
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e33103 (2012)
Little is known about safety of and adherence to intermittent HIV PrEP regimens, which may be more feasible than daily dosing in some settings. We present safety and adherence data from the first trial of an intermittent PrEP regimen among Kenyan men
Externí odkaz:
https://doaj.org/article/66012d0d97844b159d921b40df6953a5